Novo Nordisk A/S:

Novo Nordisk – major shareholder announcement

Bagsværd, Denmark, 7 June 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.

The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the entire share capital and below 5% of the voting rights.

For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). or more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Further information

Company announcement No 50 / 2022

Annex:   Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 31 May 2022

Attachment

• CA220607_Major_shareholder_information